Q32 Bio, Inc. (QTTB)
8.65
-0.15
(-1.70%)
USD |
NASDAQ |
Oct 23, 16:00
8.63
-0.02
(-0.23%)
After-Hours: 20:00
Q32 Bio Enterprise Value : 104.35M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 104.35M |
| October 22, 2026 | 107.91M |
| October 21, 2026 | 104.82M |
| October 20, 2026 | 103.64M |
| October 19, 2026 | 83.93M |
| October 16, 2026 | 77.53M |
| October 15, 2026 | 83.46M |
| October 14, 2026 | 89.16M |
| October 13, 2026 | 90.34M |
| October 12, 2026 | 106.48M |
| October 09, 2026 | 96.99M |
| October 08, 2026 | 91.06M |
| October 07, 2026 | 88.68M |
| October 06, 2026 | 91.53M |
| October 05, 2026 | 97.70M |
| October 02, 2026 | 94.38M |
| October 01, 2026 | 94.85M |
| September 30, 2026 | 95.33M |
| September 29, 2026 | 125.24M |
| September 28, 2026 | 118.11M |
| September 25, 2026 | 107.20M |
| September 24, 2026 | 117.88M |
| September 23, 2026 | 125.95M |
| September 22, 2026 | 149.92M |
| September 21, 2026 | 147.55M |
| Date | Value |
|---|---|
| September 18, 2026 | 149.21M |
| September 17, 2026 | 156.81M |
| September 16, 2026 | 159.65M |
| September 15, 2026 | 164.16M |
| September 14, 2026 | 157.99M |
| September 11, 2026 | 162.50M |
| September 10, 2026 | 153.48M |
| September 09, 2026 | 163.45M |
| September 08, 2026 | 176.51M |
| September 04, 2026 | 183.63M |
| September 03, 2026 | 202.85M |
| September 02, 2026 | 221.61M |
| September 01, 2026 | 239.88M |
| August 31, 2026 | 251.99M |
| August 28, 2026 | 255.79M |
| August 27, 2026 | 282.37M |
| August 26, 2026 | 283.08M |
| August 25, 2026 | 286.41M |
| August 24, 2026 | 287.36M |
| August 21, 2026 | 278.10M |
| August 20, 2026 | 275.49M |
| August 19, 2026 | 275.01M |
| August 18, 2026 | 261.96M |
| August 17, 2026 | 277.62M |
| August 14, 2026 | 258.64M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Intellia Therapeutics, Inc. | 1.205B |
| Beam Therapeutics, Inc. | 1.578B |
| Prime Medicine, Inc. | 680.71M |
| Prelude Therapeutics, Inc. | 155.41M |
| Twist Bioscience Corp. | 8.696B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -8.946M |
| Total Expenses (Quarterly) | 8.946M |
| EPS Diluted (Quarterly) | -0.4398 |
| Earnings Yield | 34.70% |
| Operating Earnings Yield | 16.74% |
| Normalized Earnings Yield | 34.75 |